東方網力(300367.SZ):擬放棄物靈科技增資煩的優先認購權
格隆匯 6 月 19日丨東方網力(300367.SZ)公佈,北京物靈科技有限公司(“物靈科技”)系公司參股公司,公司持有物靈科技23.69%股權。
為取得進一步發展,擴大規模,增強業務能力,物靈科技擬與蘇民投君信(上海)產業升級與科技創新股權投資合夥企業(有限合夥)(“蘇信基金”)簽訂《關於北京物靈科技有限公司的增資協議》。由蘇信基金向物靈科技增資人民幣2000萬元,取得物靈科技20%股權,全部計入註冊資本,公司及物靈科技其他股東放棄此次增資優先認購權。
上述調整完成後,物靈科技註冊資本將增加至10000萬元,公司持股比例將由23.6941%變更為18.9553%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.